FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131569310> ?p ?o ?g. }

• W3131569310 endingPage "01" @default.
• W3131569310 startingPage "OT" @default.
• W3131569310 abstract "Abstract Background: Neoadjuvant chemotherapy (NACT) results in eradication of cancer in the axillary lymph nodes in 40% to 70% of patients. This has raised questions about the benefit of further axillary treatment in these patients with no evidence of residual disease in the lymph nodes. Trial design: A multi-centre phase III randomised controlled trial with embedded economic evaluation in which participants will be randomised in a 1:1 ratio. Study participants: T1-3N1M0 breast cancer patients aged 18 years or older, with needle biopsy proven nodal metastases, who after NACT have no residual cancer in the lymph nodes on dual tracer sentinel node biopsy and removal of at least 3 lymph nodes (sentinel nodes and marked involved node). Intervention: Participants in the experimental group will not receive further axillary treatment (axillary lymph node dissection [ALND] or axillary radiotherapy [ART]), after NACT and surgery. Participants in the control group will receive further axillary treatment (ALND or ART) after NACT and surgery, as per local guidelines. Stratification: Institution, type of breast surgery (breast conserving surgery (BCS) vs mastectomy), receptor status (triple negative vs HER2 positive vs ER status positive and/or PR status positive and HER2 negative) Eligible participants will be/should have:•Age ≥ 18•Male or female •T1-3N1M0 breast cancer at diagnosis (prior to NACT) •FNA or core biopsy confirmed axillary nodal metastases at presentation •Oestrogen receptor and HER2 status evaluated on primary tumour •Received standard NACT as per local guidelines (Patients undergoing neoadjuvant endocrine therapy as part of another clinical trial are eligible) •Ultrasound of the axilla at completion of NACT •Undergo dual tracer sentinel node biopsy after NACT and at least 3 nodes removed (sentinel nodes and marked node). If axillary node sampling is performed following failed localisation of sentinel nodes, patient will be eligible if at least 3 nodes removed (including the marked node) •No evidence of nodal metastases post NACT (isolated tumour cells, micro or macro metastasis) Participants will be excluded if they have any one of the following:•Bilateral invasive breast cancer•Sentinel node biopsy prior to NACT•Marked node not removed except where at least one node removed showsoevidence of down-staging with complete pathological response e.g. fibrosis or scarring and at least 3 nodes removed•Previous axillary surgery on the same body side as the scheduled targeted sampling•Any previous cancer within last 5 years or concomitant malignancy except basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix oin situ or stage 1 melanoma, contra- or ipsilateral in situ breast cancer Specific aims: To assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment in terms of disease free survival (DFS), and reduces the risk of lymphoedema at 5 years.Statistical methods: All analyses will be carried out on an intention-to-treat basis to preserve randomisation, avoid bias from exclusions and preserve statistical power. Target accrual: 1900, Number of sites: ~100 ClinicalTrials.gov: NCT04109079 Contact information: atnec@warwick.ac.uk Disclaimer: This study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (Reference - HTA NIHR128311). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Citation Format: Amit Goyal, Sophie Cramp, Duncan Wheatley, Andrea Marshall, Shama Puri, Tara Homer, Luke Vale, Romaana Mir, Zohal Nabi, Janice Rose, Helen Teresa Edwards, Samreen Ahmed, Abeer Shaaban, Beatrix Elsberger, Julie Bruce, Sophie Gasson, Valerie Speirs, Jacqui Shaw, Helen Higgins, Janet Dunn. Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy - ATNEC (ClinicalTrials.gov NCT04109079) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-04-01." @default.
• W3131569310 created "2021-03-01" @default.
• W3131569310 creator A5000940073 @default.
• W3131569310 creator A5004074922 @default.
• W3131569310 creator A5018809857 @default.
• W3131569310 creator A5019673641 @default.
• W3131569310 creator A5021383689 @default.
• W3131569310 creator A5026280980 @default.
• W3131569310 creator A5028914408 @default.
• W3131569310 creator A5031415556 @default.
• W3131569310 creator A5038287316 @default.
• W3131569310 creator A5039709865 @default.
• W3131569310 creator A5042425900 @default.
• W3131569310 creator A5043221376 @default.
• W3131569310 creator A5043611963 @default.
• W3131569310 creator A5043843072 @default.
• W3131569310 creator A5045373037 @default.
• W3131569310 creator A5050184275 @default.
• W3131569310 creator A5053885717 @default.
• W3131569310 creator A5062027183 @default.
• W3131569310 creator A5068874700 @default.
• W3131569310 creator A5079946366 @default.
• W3131569310 date "2021-02-15" @default.
• W3131569310 modified "2023-09-27" @default.
• W3131569310 title "Abstract OT-04-01: Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy - ATNEC (ClinicalTrials.gov NCT04109079)" @default.
• W3131569310 doi "https://doi.org/10.1158/1538-7445.sabcs20-ot-04-01" @default.
• W3131569310 hasPublicationYear "2021" @default.
• W3131569310 type Work @default.
• W3131569310 sameAs 3131569310 @default.
• W3131569310 citedByCount "0" @default.
• W3131569310 crossrefType "journal-article" @default.
• W3131569310 hasAuthorship W3131569310A5000940073 @default.
• W3131569310 hasAuthorship W3131569310A5004074922 @default.
• W3131569310 hasAuthorship W3131569310A5018809857 @default.
• W3131569310 hasAuthorship W3131569310A5019673641 @default.
• W3131569310 hasAuthorship W3131569310A5021383689 @default.
• W3131569310 hasAuthorship W3131569310A5026280980 @default.
• W3131569310 hasAuthorship W3131569310A5028914408 @default.
• W3131569310 hasAuthorship W3131569310A5031415556 @default.
• W3131569310 hasAuthorship W3131569310A5038287316 @default.
• W3131569310 hasAuthorship W3131569310A5039709865 @default.
• W3131569310 hasAuthorship W3131569310A5042425900 @default.
• W3131569310 hasAuthorship W3131569310A5043221376 @default.
• W3131569310 hasAuthorship W3131569310A5043611963 @default.
• W3131569310 hasAuthorship W3131569310A5043843072 @default.
• W3131569310 hasAuthorship W3131569310A5045373037 @default.
• W3131569310 hasAuthorship W3131569310A5050184275 @default.
• W3131569310 hasAuthorship W3131569310A5053885717 @default.
• W3131569310 hasAuthorship W3131569310A5062027183 @default.
• W3131569310 hasAuthorship W3131569310A5068874700 @default.
• W3131569310 hasAuthorship W3131569310A5079946366 @default.
• W3131569310 hasConcept C121608353 @default.
• W3131569310 hasConcept C126322002 @default.
• W3131569310 hasConcept C126838900 @default.
• W3131569310 hasConcept C141071460 @default.
• W3131569310 hasConcept C143998085 @default.
• W3131569310 hasConcept C2775934546 @default.
• W3131569310 hasConcept C2776608951 @default.
• W3131569310 hasConcept C2777649267 @default.
• W3131569310 hasConcept C2777757722 @default.
• W3131569310 hasConcept C2778292576 @default.
• W3131569310 hasConcept C2780212769 @default.
• W3131569310 hasConcept C2908949552 @default.
• W3131569310 hasConcept C509974204 @default.
• W3131569310 hasConcept C530470458 @default.
• W3131569310 hasConcept C71924100 @default.
• W3131569310 hasConceptScore W3131569310C121608353 @default.
• W3131569310 hasConceptScore W3131569310C126322002 @default.
• W3131569310 hasConceptScore W3131569310C126838900 @default.
• W3131569310 hasConceptScore W3131569310C141071460 @default.
• W3131569310 hasConceptScore W3131569310C143998085 @default.
• W3131569310 hasConceptScore W3131569310C2775934546 @default.
• W3131569310 hasConceptScore W3131569310C2776608951 @default.
• W3131569310 hasConceptScore W3131569310C2777649267 @default.
• W3131569310 hasConceptScore W3131569310C2777757722 @default.
• W3131569310 hasConceptScore W3131569310C2778292576 @default.
• W3131569310 hasConceptScore W3131569310C2780212769 @default.
• W3131569310 hasConceptScore W3131569310C2908949552 @default.
• W3131569310 hasConceptScore W3131569310C509974204 @default.
• W3131569310 hasConceptScore W3131569310C530470458 @default.
• W3131569310 hasConceptScore W3131569310C71924100 @default.
• W3131569310 hasIssue "4_Supplement" @default.
• W3131569310 hasLocation W31315693101 @default.
• W3131569310 hasOpenAccess W3131569310 @default.
• W3131569310 hasPrimaryLocation W31315693101 @default.
• W3131569310 hasRelatedWork W1897732497 @default.
• W3131569310 hasRelatedWork W1977676876 @default.
• W3131569310 hasRelatedWork W2028565633 @default.
• W3131569310 hasRelatedWork W2045716044 @default.
• W3131569310 hasRelatedWork W2085188520 @default.
• W3131569310 hasRelatedWork W2101368045 @default.
• W3131569310 hasRelatedWork W2372911794 @default.
• W3131569310 hasRelatedWork W2397280141 @default.
• W3131569310 hasRelatedWork W2758222867 @default.
• W3131569310 hasRelatedWork W3171847502 @default.
• W3131569310 hasVolume "81" @default.
• W3131569310 isParatext "false" @default.
• W3131569310 isRetracted "false" @default.

• next